环孢素A与干扰素联合逆转复发难治性急性白血病多药耐药的临床研究

Clinical study on reversal of multidrug resistance in relapsed or refractory acute leukemias by cyclosporin A and interferon

目的:探讨环孢素A(CsA)与干扰素α(IFN-α)联合逆转复发难治性急性白血病(AL)多药耐药(MDR)的临床疗效。方法:采用免疫细胞化学ABC法和P-170单抗JSB-1对50例复发难治性AL患者进行P-170检测,并对其中34例P-170阳性患者随机分为逆转组(CsA加IFN-α联合化疗)及对照组(单用化疗)进行逆转MDR的研究。结果:P-170在复发难治性急性AL中有高表达(68％),逆转组逆转MDR的总有效率(64.7％)明显高于对照组(23.5％),统计学分析差异有显著性意义(P<0.05)。结论:CsA与IFN-α联合应用有可能成为较为安全有效的血液病逆转方法,在治疗复发难治性AL中具有良好的临床应用前景。

Objective:To explore the clinical implication of reversal of multidrug resistance (MDR) by cyclos-porin A (CsA) and interferon-a (IFN-α). Method:The expression of P-170 were assaied in 50 cases of relapsed or refractory acute leukemias by means of immunocytochemistry (Avidin-Biotin complex, ABC) using a monoclonal antibody JSB-1 against P-170. The 34 cases who were the P-170 positive were randomly divided into two groups; trial group (chemotherapy plus CsA and IFN-a) and control group(chemotherapy alone). Result: The incidence of P-170 expression (68%) was higher in relapsed or refractory acute leukemias. The effective rate were 64. 7% and 23.5% respectively ( P <0. 05). Conclusion:CsA and IFN-o were safe and effective for reversal of MDR in relapsed or refractory acute leukemia.